Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 28

Sort by

Sort Order Select

Journal Articles

Identification of a Circulating Serum miRNA Signature As a Predictive Biomarker and Potential Therapeutic Target in Diffuse Large B-Cell Lymphoma

Giulia Regazzo, Giulia Vari, Francesco Marchesi, Andrea Sacconi, Francesca Palombi, Mariangela Novello, Elena Papa, Martina Tomassi, Francesco Pisani, Andrea Mengarelli, Maria Giulia Rizzo

Blood (2024) 144 (Supplement 1): 6216.

https://doi.org/10.1182/blood-2024-203384

Published: 2024

Journal Articles

Long Term Survival in Multiple Myeloma Patients: A Multicenter Italian Experience

Blood (2022) 140 (Supplement 1): 7147–7149.

https://doi.org/10.1182/blood-2022-165338

Published: 2022

Journal Articles

On-Demand Plerixafor with Cyclophosphamide and G-CSF for Hematopoietic Stem-Cell Mobilization in Multiple Myeloma Patients: Preliminary Results of a Prospective Observational Study (MOZOBL06877)

Blood (2020) 136 (Supplement 1): 13–14.

https://doi.org/10.1182/blood-2020-136316

Published: 2020

Journal Articles

Poor Prognosis of Multiple Myeloma Predicted By High Levels of Circulating Plasma Cells Is Independent from Other High-Risk Features but Is Modulated By the Achievement of Minimal Residual Disease Negativity

Blood (2020) 136 (Supplement 1): 12–13.

https://doi.org/10.1182/blood-2020-137075

Published: 2020

Journal Articles

Integrative Analysis of Baseline Prognostic Features and Achievement of Minimal Residual Disease Negativity As Predictors of Early Relapse in Transplant-Eligible Multiple Myeloma Patients

Blood (2019) 134 (Supplement_1): 605.

https://doi.org/10.1182/blood-2019-125588

Published: 2019

Journal Articles

Carfilzomib-Lenalidomide-Dexamethasone (KRd) Induction-Autologous Transplant (ASCT)-Krd Consolidation Vs KRd 12 Cycles Vs Carfilzomib-Cyclophosphamide-Dexamethasone (KCd) Induction-ASCT-KCd Consolidation: Analysis of the Randomized Forte Trial in Newly Diagnosed Multiple Myeloma (NDMM)

Blood (2018) 132 (Supplement 1): 121.

https://doi.org/10.1182/blood-2018-99-112093

Published: 2018

Journal Articles

Real Life Use of Bendamustine Plus Rituximab Versus Chlorambucil Plus Rituximab As Front-Line Therapy for Elderly CLL Patients. Retrospective Multicenter Study in the Lazio Region

Francesco Autore, MD, Idanna Innocenti, MD PhD, Francesco Corrente, Maria Ilaria Del Principe, MD, Serena Rosati, MD, Paolo Falcucci, Esmeralda Conte, Maria Assunta Limongiello, Daniela Renzi, Laura De Padua, MD, Alessandro Andriani, MD, Francesco Pisani, MD, Giuseppe Cimino, Agostino Tafuri, MD, Marco Montanaro, MD, Francesca Romana Mauro, Giovanni Del Poeta, MD, Luca Laurenti, MD

Blood (2018) 132 (Supplement 1): 5550.

https://doi.org/10.1182/blood-2018-99-119408

Published: 2018

Journal Articles

R-CHOP Preceded By Engineered Tumor Necrosis Factor (TNF) in Patients with Relapsed or Refractory (r/r) Primary CNS Lymphoma (PCNSL): Results of Antitumor Activity, Safety and Blood-Brain Barrier (BBB) Permeabilization in the "Ingrid" Phase II Trial

Blood (2018) 132 (Supplement 1): 1687.

https://doi.org/10.1182/blood-2018-99-118507

Published: 2018

Journal Articles

A Randomized Study of Carfilzomib-Lenalidomide-Dexamethasone Vs Carfilzomib-Cyclophosphamide-Dexamethasone Induction in Newly Diagnosed Myeloma Patients Eligible for Transplant: High Efficacy in High- and Standard-Risk Patients

Blood (2017) 130 (Supplement 1): 4541.

https://doi.org/10.1182/blood.V130.Suppl_1.4541.4541

Published: 2017

Journal Articles

Effects on Survival and Neurocognitive Functions of Whole-Brain Radiotherapy (WBRT) and Autologous Stem Cell Transplantation (ASCT) as Consolidation Options after High-Dose Methotrexate-Based Chemoimmunotherapy in Patients with Newly Diagnosed Primary CNS Lymphoma (PCNSL): Results of the Second Randomization of the IELSG32 Trial

Andrés J.M. Ferreri, MD, Kate Cwynarski, MBBS, FRPATH, PhD, Elisa Jacobsen Pulczynski, MD, Christopher P. Fox, MBChB, PhD, Elisabeth Schorb, MD, Paul La Rosée, MD, Mascha Binder, MD, Alberto Fabbri, MD, Valter Torri, MD, Eleonora Minacapelli, MD, Monica Falautano, MD, Fiorella Ilariucci, MD, Achille Ambrosetti, MD, Alexander Röth, MD, Claire Jane Hemmaway, MD, Peter M Johnson, MA, MD, Kim Linton, MBChB, MRCP, PhD, Tobias Pukrop, MD, Jette Sonderskov Gorlov, MD, Monica Balzarotti, MD, Georg Hess, MD, Ulrich Keller, MD, Stephan Stilgenbauer, MD, Jens P. Panse, MD, Alessandra Tucci, MD, Lorella Orsucci, MD, Francesco Pisani, MD, Alessandro Levis, MD, Stefan W. Krause, MD, Hans-Joachim Schmoll, MD PhD, Bernd Hertenstein, MD, Mathias Rummel, MD PhD, Jeffery Smith, MD, Michael Pfreundschuh, MD, PhD, Giuseppina Cabras, MD, Francesco Angrilli, MD, Maurilio Ponzoni, MD, Martina Deckert, MD, Letterio S. Politi, MD, Jurgen Finke, MD, Michele Reni, MD, Franco Cavalli, Emanuele Zucca, Gerald Illerhaus, MD

Blood (2016) 128 (22): 511.

https://doi.org/10.1182/blood.V128.22.511.511

Published: 2016

Journal Articles

Multicenter Retrospective Observational Study to Assess the Clinical Characteristics and the Outcome of Patients with Relapsed or Refractory Mantle Cell Non-Hodgkin's Lymphoma Treated in Italy According to the Ibrutinib Named Patient Program

Vittorio Stefoni, Federico Sottotetti, Manuel Gotti, Michele Spina, Stefano Volpetti, Simone Ferrero, Francesco Spina, MD, Francesco Pisani, Michele Merli, Carlo Visco, MD, Rossella Paolini, Vittorio Ruggero Zilioli, Luca Baldini, MD Prof, Nicola Di Renzo, Patrizia Tosi, Nicola Cascavilla, MD, Stefano Molica, MD, Lisa Argnani, Pier Luigi Zinzani, MD PhD

Blood (2016) 128 (22): 2985.

https://doi.org/10.1182/blood.V128.22.2985.2985

Published: 2016

Journal Articles

Different Levels of Alkaline Phospatase (ALP) in Multiple Myeloma (MM) and SOLID Tumors with BONE Lesions

Ombretta Annibali, MDPhD, Maria Teresa Petrucci, MD, Daniele Santini, MD, Elisabetta Lisi, PhD, MArco Mariani, Francesco Pisani, Member, ID:, 1012314, Velia Bongarzoni, Olga Venditti, MD, Angela Rago, Elisabetta Cerchiara, MD, Alessia Fiorini, MD, Luca Franceschini, MD, Stefano Felici, MD, MArco Russano, MD, Francesco PAntano, MD, Giuseppe Avvisati, MD PhD

Blood (2015) 126 (23): 5359.

https://doi.org/10.1182/blood.V126.23.5359.5359

Published: 2015

Journal Articles

FCR (Fludarabine, Cyclophosphamide, Rituximab) Followed By 90 yttrium Ibritumomab Tiuxetan for the Treatment of Relapsed Grades 1 and 2 Follicular Lymphoma. Long Term Efficacy and Safety Results of 9 Cases

Francesco Pisani, Member, ID:, 1012314, Maria Laura Dessanti, MD, Diana Giannarelli, MS, Ramy Kayal, MD, Francesco Marchesi, MD, Rosa Sciuto, MD, Sandra Rea, MD, Carlo Ludovico Maini, MD, Mirella Marino, MD

Blood (2014) 124 (21): 5452.

https://doi.org/10.1182/blood.V124.21.5452.5452

Published: 2014

Journal Articles

Long-Term Molecular Results Of The Gimema VEL-03-096 Trial: Molecular Remission Achievement and Loss Are Major Outcome Predictors

Blood (2013) 122 (21): 2077.

https://doi.org/10.1182/blood.V122.21.2077.2077

Published: 2013

Journal Articles

LONG-TERM RESULTS of the GIMEMA VTD Consolidation TRIAL In Autografted MULTIPLE Myeloma PATIENTS (VEL-03-096): IMPACT of Minimal RESIDUAL DISEASE Detection by REAL Time Quantitative PCR On LATE Recurrences and Overall SURVIVAL

Blood (2011) 118 (21): 827.

https://doi.org/10.1182/blood.V118.21.827.827

Published: 2011

Journal Articles

Bortezomib-Thalidomide-Dexamethasone Compared with Thalidomide-Dexamethasone as Induction and Consolidation Therapy Before and After Double Autologous Transplantation In Newly Diagnosed Multiple Myeloma: Results From a Randomized Phase 3 Study

Blood (2010) 116 (21): 42.

https://doi.org/10.1182/blood.V116.21.42.42

Published: 2010

Journal Articles

Melphalan 200 mg/m 2 versus melphalan 100 mg/m 2 in newly diagnosed myeloma patients: a prospective, multicenter phase 3 study

Blood (2010) 115 (10): 1873–1879.

https://doi.org/10.1182/blood-2009-09-241737

Published: 2010

Journal Articles

Complete Response to First-Line Bortezomib-Thalidomide-Dexamethasone Therapy in Multiple Myeloma Patients with t(4;14): Analysis of Gene Expression Profile.

Blood (2009) 114 (22): 2811.

https://doi.org/10.1182/blood.V114.22.2811.2811

Published: 2009

Journal Articles

Evolution of Bisphosphonates RELATED Osteonecrosis of the Jaw (BRONJ) IN PATIENTS with MULTIPLE MYELOMA (MM) and WALDENSTROM'S Macroglobulinemia (WM): A Retrospective STUDY.

Alessandro Andriani, MD, Maria Teresa Petrucci, MD, Tommaso Caravita, M.D., Marco Montanaro, MD, Francesco Pisani, MD, Ugo Coppetelli, MD, Marianna De Muro, MD, Velia Bongarzoni, MD, Giuseppe Avvisati, MD, Nicoletta Villivà, MD, Anna Levi, MD, Agostina Siniscalchi, MD, Alessandro Agrillo, MD, Domenico Gaglioti, MD

Blood (2009) 114 (22): 2818.

https://doi.org/10.1182/blood.V114.22.2818.2818

Published: 2009

Journal Articles

Correlation Between Clinical Outcome and Disease Kinetics by Quantitative PCR in Myeloma Patients Following Post-Transplant Consolidation with Bortezomib, Thalidomide and Dexamethasone.

Blood (2009) 114 (22): 960.

https://doi.org/10.1182/blood.V114.22.960.960

Published: 2009

NARROW

Identification of a Circulating Serum miRNA Signature As a Predictive Biomarker and Potential Therapeutic Target in Diffuse Large B-Cell Lymphoma

Long Term Survival in Multiple Myeloma Patients: A Multicenter Italian Experience

On-Demand Plerixafor with Cyclophosphamide and G-CSF for Hematopoietic Stem-Cell Mobilization in Multiple Myeloma Patients: Preliminary Results of a Prospective Observational Study (MOZOBL06877)

Poor Prognosis of Multiple Myeloma Predicted By High Levels of Circulating Plasma Cells Is Independent from Other High-Risk Features but Is Modulated By the Achievement of Minimal Residual Disease Negativity

Integrative Analysis of Baseline Prognostic Features and Achievement of Minimal Residual Disease Negativity As Predictors of Early Relapse in Transplant-Eligible Multiple Myeloma Patients

Carfilzomib-Lenalidomide-Dexamethasone (KRd) Induction-Autologous Transplant (ASCT)-Krd Consolidation Vs KRd 12 Cycles Vs Carfilzomib-Cyclophosphamide-Dexamethasone (KCd) Induction-ASCT-KCd Consolidation: Analysis of the Randomized Forte Trial in Newly Diagnosed Multiple Myeloma (NDMM)

Real Life Use of Bendamustine Plus Rituximab Versus Chlorambucil Plus Rituximab As Front-Line Therapy for Elderly CLL Patients. Retrospective Multicenter Study in the Lazio Region

R-CHOP Preceded By Engineered Tumor Necrosis Factor (TNF) in Patients with Relapsed or Refractory (r/r) Primary CNS Lymphoma (PCNSL): Results of Antitumor Activity, Safety and Blood-Brain Barrier (BBB) Permeabilization in the "Ingrid" Phase II Trial

A Randomized Study of Carfilzomib-Lenalidomide-Dexamethasone Vs Carfilzomib-Cyclophosphamide-Dexamethasone Induction in Newly Diagnosed Myeloma Patients Eligible for Transplant: High Efficacy in High- and Standard-Risk Patients

Multicenter Retrospective Observational Study to Assess the Clinical Characteristics and the Outcome of Patients with Relapsed or Refractory Mantle Cell Non-Hodgkin's Lymphoma Treated in Italy According to the Ibrutinib Named Patient Program

Different Levels of Alkaline Phospatase (ALP) in Multiple Myeloma (MM) and SOLID Tumors with BONE Lesions

FCR (Fludarabine, Cyclophosphamide, Rituximab) Followed By 90 yttrium Ibritumomab Tiuxetan for the Treatment of Relapsed Grades 1 and 2 Follicular Lymphoma. Long Term Efficacy and Safety Results of 9 Cases

Long-Term Molecular Results Of The Gimema VEL-03-096 Trial: Molecular Remission Achievement and Loss Are Major Outcome Predictors

LONG-TERM RESULTS of the GIMEMA VTD Consolidation TRIAL In Autografted MULTIPLE Myeloma PATIENTS (VEL-03-096): IMPACT of Minimal RESIDUAL DISEASE Detection by REAL Time Quantitative PCR On LATE Recurrences and Overall SURVIVAL

Bortezomib-Thalidomide-Dexamethasone Compared with Thalidomide-Dexamethasone as Induction and Consolidation Therapy Before and After Double Autologous Transplantation In Newly Diagnosed Multiple Myeloma: Results From a Randomized Phase 3 Study

Melphalan 200 mg/m 2 versus melphalan 100 mg/m 2 in newly diagnosed myeloma patients: a prospective, multicenter phase 3 study

Complete Response to First-Line Bortezomib-Thalidomide-Dexamethasone Therapy in Multiple Myeloma Patients with t(4;14): Analysis of Gene Expression Profile.

Evolution of Bisphosphonates RELATED Osteonecrosis of the Jaw (BRONJ) IN PATIENTS with MULTIPLE MYELOMA (MM) and WALDENSTROM'S Macroglobulinemia (WM): A Retrospective STUDY.

Correlation Between Clinical Outcome and Disease Kinetics by Quantitative PCR in Myeloma Patients Following Post-Transplant Consolidation with Bortezomib, Thalidomide and Dexamethasone.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only